Selexis and Generium launched an omalizumab biosimilar on the Russian market; Remsima sales hit a record high for Celltrion Healthcare; Xbrane Biopharma shares long-term results for its ranibizumab biosimilar.
Selexis and Generium shared that they have launched Genolar, a biosimilar for omalizumab (Xolair) on the Russian market for the treatment of persistent atopic bronchial asthma and resistant chronic idiopathic urticaria for patients aged 6 years and up.
“Individuals coping with chronic diseases such as atopic asthma deserve access to novel, affordable medicines. The introduction of effective biosimilars like Genolar makes that possible, while also aligning with Selexis’ patient-centric mission,” said Roland Hecht, PhD, chief business officer at Selexis.
The drug is the first Selexis SUREtechnology Platform-generated biosimilar to reach that market under a commercialization partnership with Generium. The biosimilar is also cleared for use in patients with chronic spontaneous urticaria in patients aged 12 years and older with elevated immunoglobulin E (IgE) who are unresponsive to antihistamine treatment. Omalizumab is a recombinant humanized monoclonal antibody that bind to free human IgE.
According to Yonhap News Agency, sales of Celltrion Healthcare’s infliximab biosimilar Remsima reached a new record in 2021 in the United States, jumping up 13% in year-over-year growth to $385 million.
Remsima references Remicade and has been on the US market since November 2016, when it launched under the name Inflectra as part of a commercialization partnership between Celltrion and Pfizer. Remsima is used to treat patients with rheumatoid arthritis and several other rheumatologic conditions.
At the end of 2021, the market share for the biosimilar amounted to 22.3% in the United States, which is lower than Remicade’s 67.2% market share but it is still gaining traction. Over the last 5 years, sales of the reference product had been cut by nearly half, from $4.5 billion in 2017 to $2 billion in 2021, following the launch of Celltrion’s product.
The news of the record breaking growth comes around the same time as Hikma Pharmaceuticals announced the expansion in its licensing agreement with Celltrion over the subcutaneous version of Remsima for their Middle Eastern and North African (MENA) markets. The expansion builds on the companies’ existing partnership for 3 biosimilar products, including Truxima (rituximab), the original Remsima formulation, and Herzuma (trastuzumab).
“Subcutaneous administration has been shown to be effective, safe, well-tolerated and generally preferred by patients. This new formulation enables administration outside of the hospital setting, allowing more patients access to the treatment,” said Mazen Darwazah, the executive vice chairman of Hikma and president of MENA.
Hikma’s MENA markets include those in Algeria, Egypt, Iraq, Jordan, Morocco, Tunisia, the United Arab Emirates, and Saudi Arabia.
Xbrane Biopharma announced positive phase 3 trial results demonstrating equivalent efficacy for its ranibizumab biosimilar Xlucane in comparison with the reference product (Lucentis) over 12 months.
The company said that the results will help the company along its journey for regulatory approval for various markets. Ranibizumab is a blood vessel growth inhibitor used to treat neovascular age-related macular degeneration (wet AMD), macular edema, and diabetic retinopathy.
The company said that the Xplore study results revealed no clinically meaningful differences in safety, efficacy, pharmacokinetics, or immunogenicity between the 2 drugs. The Xplore study is a randomized, double-blinded, multi-center study comparing the safety and efficacy properties of Xlucane compared with the reference product in patients with wet AMD. The study pulls data from 583 patients from 140 clinics in 15 countries.
Previous data shared from the trial demonstrated equivalent efficacy in the change of best corrected visual acuity after 8 weeks of treatment compared to the reference product.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.